Conference
Abstract 1481: Preclinical validation of a novel CD133/CD3 bispecific T-cell engager (BiTE) antibody to target patient-derived glioblastoma cells
Abstract
Abstract
Glioblastoma (GBM), an aggressive primary brain tumor in adults, is feared for its near uniformly fatal prognosis and is characterized by a diverse cellular phenotype and genetic heterogeneity. Despite the use of aggressive multi-modal treatment including surgical resection, radiotherapy and chemotherapy, the outcome of patients with GBM has failed to improve significantly. We developed patient-derived brain tumor …
Authors
Vora P; Venugopal C; Adams J; Pan J; Chokshi C; Qazi M; Subapanditha M; Singh M; Bakhshinyan D; Bezverbnaya K
Volume
76
Pagination
pp. 1481-1481
Publisher
American Association for Cancer Research (AACR)
Publication Date
July 15, 2016
DOI
10.1158/1538-7445.am2016-1481
Conference proceedings
Cancer Research
Issue
14_Supplement
ISSN
0008-5472